The cytochrome P-450 1A2 (CYP1A2) enzyme accounts for approximately 13% of the CYP family of enzymes. (1) It metabolises drugs and is important for drug-drug interactions. Interindividual di erences in CYP1A2 phenotype and genotype result in variable enzyme expression and functional activity, thus can alter drug plasma concentration. Ca eine is largely metabolised by CYP1A2 and is o en used to investigate an individual's CYP1A2 metabolic activity, (2) which may help in drug prescription and dose adjustment to avoid toxicity or ine cacy. (3) The aim of this project is to develop two protocols:
The ELISA standard curve was generated on myassays.com using four-parameter logistic curve t. Pharmacokinetic parameters of ca eine were determined; coe cient of variation (CV) was calculated to evaluate precision and repeatability of the immunoassay. Data were analysed using GraphPad Prism 7.04 and expressed as mean ± SD.
Development of PCR-RFLP assay to determine a SNP in the CYP1A2 gene
DNA was isolated from buccal cells of three volunteers using two commercially available DNA extraction kits. It was used for identi cation of CYP1A2*1F through PCR-RFLP, and its association with the fast metaboliser phenotype using two published protocols. (5-6) Two pairs of forward and reverse primers were evaluated to identify and amplify gene segment containing the rs762551 SNP. PCR products were digested using two restriction enzymes speci c for the C-allele. Fragments were analysed by agarose gel electrophoresis.
Results

Development, optimization and validation of ca eine competitive ELISA
The optimised ELISA allowed detection of ca eine ranging from 0.169 ng/ml -20.0 ng/ml in saliva. CV between days was <15%, and <5% between replicates, indicating the ELISA had acceptable precision and repeatability. Saliva was collected before taking the ca eine tablet, then at 0.5, 1, 2, 3, 5, 7, 9, 12 and 24 hours. Levels of ca eine from 1 to 12 hours was statistically di erent from baseline at 0 hour (p = <0.05) and peaked at 1.56 ± 0.98 hours. Large interindividual variations were observed in Cmax (1215 ± 2927 ng/ml).
PCR-RFLP assay to determine a SNP in the CYP1A2 gene
The PCR-RFLP did not yield any restriction fragments, suggesting all three subjects had two copies of the most common A-allele. Use of a control restriction enzyme, which cuts outside the SNP, yielded fragments within the expected base pair range, demonstrating validity of the assay. Further development of the PCR-RFLP protocol is required to determine CYP1A2*1F genotype.
Discussion
ELISA and CYP1A2 phenotype
Competitive ELISA, optimized and validated, is sensitive enough to quantify salivary ca eine; it is comparable to Carvalho's immunoassay (7) and a commercial ELISA kit using similar antibodies. (8) Large interindividual variations in Cmax and Tmax may represent di erences in CYP1A2 activity or that ca eine's pharmacokinetic may not accurately represent CYP1A2 metabolic activity. Further study with a larger sample size is required.
PCR-RFLP and CYP1A2 genotype
The PCR-RFLP assay requires further optimization and a larger sample size to identify CYP1A2*1F. In addition to the enzymes speci c for C-allele, those speci c for A-allele could be used.
Are the protocols appropriate for teaching the concepts of pharmacogenomics to undergraduate students?
The competitive ELISA o ers a simple and inexpensive way to quantify salivary ca eine in a standard laboratory, making it suitable for undergraduate laboratory teaching. During the experiments, students can practise laboratory skills, learn the principles of ELISA, understand pharmacokinetics and drug metabolism. Fast metabolisers metabolise drugs quickly, resulting in drug ine cacy; whereas drugs may accumulate in slow metabolisers, leading to toxicity. Through understanding the metaboliser phenotypes, drug dose can be adjusted accordingly for maximum e cacy and to avoid side e ect. Many factors a ect CYP1A2 phenotype, but their mechanisms and impact are unclear. The signi cance of di erent genotypes on its phenotype also has to be con rmed. The current PCR-RFLP protocol is not appropriate for undergraduate laboratory and requires further optimization.
Lessons Learnt
Constant re ection on the experimental process was required to produce an optimised immunoassay for the accurate quanti cation of salivary ca eine level.
As it was the rst time carrying out a laboratory project by myself, I felt quite uncertain initially. However, under the guidance of my supervisors and reading the literature, I quickly understood and became more interested in laboratory research. I was surprised by the viscosity of saliva and it was hard to pipette. In later experiments, to minimize error in volume of saliva used, a larger volume was pipetted and vortexed a er each dilution. In addition, large interindividual di erences were observed in ca eine pharmacokinetic. This may be due to saliva collection not being monitored; the duration of saliva collection could be standardised. Moreover, it may be accounted for by di erences in gastric emptying. Large volume and high density food are emptied slower, (9) which may a ect ca eine absorption rate. Some volunteers fasted before taking ca eine tablets, whereas others did not. This increased my understanding on the interaction between drug pharmacokinetics and consumption of food or liquid. Mealtime and saliva collection times should be standardized in order to minimize interference of food in future experiments. Moreover, pharmacokinetics of ca eine could be a ected by di erences in body mass, smoking and other drugs, which should be considered in the future.
